Abstract 24P
Background
Genetic testing for hereditary cancer is important for clinical treatment and risk management for patients and high-risk individuals. The landscape of genetic testing for germline cancer predisposition has shifted from single gene testing to the more cost-effective multi-gene panels. However, multi-gene panel testing results in greater variant of uncertain significance (VUS) rates and secondary findings, which is challenging for clinical management. In this study, we aim to describe the genetic testing uptake and variant distribution in a single genetic counselling and testing centre in Malaysia.
Methods
A descriptive retrospective analysis of patients seen at a single genetic counselling and testing centre was conducted. Patients were referred from clinicians or self-referred from January 2019 until December 2022. Researchers conducted intake calls, collected pedigrees and written informed consent from all patients prior to genetic testing. Pre and post-test genetic counseling was provided by the certified genetic counselor. Patients were offered either physical consultation or telegenetic counselling. Multi-gene panels were used to analyze between 19 to 47 genes which are associated with an increased risk of hereditary cancer.
Results
Among the 489 who were referred, 430 (88%) came forward for genetic counseling, the majority of them were referred from private hospitals within the Klang Valley. Among the 381 (89%) who proceeded with genetic testing, 13.9% had pathogenic/likely pathogenic variants, 24.4%, variant of uncertain significance and 61.7% had no variants detected. Majority of the patients had breast cancer (77%) and 84% met current genetic testing guidelines criteria.
Conclusions
The uptake rate of genetic testing is high after pre-test genetic counselling. However, there is a high rate of VUS which causes uncertainties for the patients and their clinicians in making clinical management decisions. Adequate pre and post-test genetic counseling can ensure a better understanding of these variants’ implication and provide support of potential psychosocial impact to the patient.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Cancer Research Malaysia.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract